10-Q: Greater Cannabis Faces Deepening Losses, Going Concern Doubt

The Greater Cannabis Company reported a significantly increased net loss and substantial dilution for Q2 2025, raising substantial doubt about its ability to continue as a going concern.

Summary

• The company reported no revenue for the six months ended June 30, 2025, consistent with the prior year.
• Net loss for the six months ended June 30, 2025, dramatically increased to $633,270, up from $89,528 for the same period in 2024.
• Operating expenses rose to $91,787 for the six months ended June 30, 2025, compared to $78,208 in 2024.
• Other expenses surged to $541,483 in Q2 2025, primarily due to a $232,220 loss on conversion of notes payable and $306,323 in note default penalties and interest.
• Cash balance decreased to $26,712 as of June 30, 2025, from $57,368 at December 31, 2024.
• Total current liabilities increased to $1,098,955 as of June 30, 2025, from $898,058 at December 31, 2024.
• The company had negative working capital of $1,072,243 as of June 30, 2025.
• Weighted average common shares outstanding increased to 1,098,585,286 for the six months ended June 30, 2025, from 804,638,436 in 2024, reflecting significant dilution.
• As of August 4, 2025, 1,349,888,436 shares of common stock were outstanding.

Sentiment

Score: 1

Explanation: The company is in severe financial distress, reporting a significantly increased net loss, critically low cash, and substantial liabilities. There is explicit 'substantial doubt' about its ability to continue as a going concern, coupled with ongoing internal control weaknesses and massive shareholder dilution. This indicates an extremely negative outlook.

Positives

• Cash used in operating activities decreased to $30,656 for the six months ended June 30, 2025, from $86,543 in the prior year, indicating a slower burn rate from operations, though still negative.

Negatives

• The company continues to generate no revenue from product sales or consulting fees.
• Net loss increased significantly by over 600% year-over-year for the six-month period.
• A substantial portion of the increased loss is attributed to non-operating items like loss on conversion of notes payable ($232,220) and note default penalties and interest ($306,323).
• The company's cash balance is critically low at $26,712.
• Total current liabilities exceed total assets, resulting in a significant stockholders' deficiency of $1,072,243.
• The company has issued a large number of common shares (545,250,000 shares in the six months ended June 30, 2025) for notes payable conversion and accrued compensation, leading to substantial dilution for existing shareholders.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern through June 2026.

Risks

• Inability to remediate identified material weaknesses in internal control over financial reporting and disclosure controls and procedures.
• Failure to meet the requirements of agreements under which business interests were acquired, potentially leading to loss of operating rights.
• Inability to secure additional financing in the near future to commence and sustain planned development and growth plans.
• Inability to attract, retain, and motivate qualified personnel, including employees, consultants, and contractors.
• Risks and uncertainties relating to the various industries and operations the company is currently engaged in.
• Uncertainty that future growth, development, or expansion will be consistent with expectations.
• Inherent uncertainty of business operations, including profit, cost of goods, production costs, and cost estimates, with potential for unexpected costs and expenses.
• Risks related to commodity price fluctuations.
• Uncertainty of profitability based on a history of losses.
• Risks related to failure to obtain adequate financing on a timely basis and on acceptable terms for planned development projects.
• Risks related to environmental regulation and liability.
• Risks related to tax assessments.
• The company's current financial condition raises substantial doubt about its ability to continue as a going concern through June 2026.
• Lack of additional capital from operations or external sources could force the company to substantially curtail or cease operations.
• No assurance that required funds, if available, will be on attractive terms or will not have a significant dilutive effect on existing shareholders.

Future Outlook

The company plans to further develop its novel cannabinoid therapeutic and conduct clinical studies, which are expected to require an investment of up to $1,000,000 and up to two years to finalize. The current business plan also includes concentrating on cannabis-related investment and development opportunities through direct equity investments, joint ventures, licensing agreements, or acquisitions. The company's future plans include securing additional funding sources to address its going concern issues.

Management Comments

• "Although the Company was able to launch the product and received some limited initial orders, Greater Cannabis management ultimately elected to pursue other opportunities which they believed offered the Company greater potential for growth and ultimate profitability."
• "The Company plans to further develop this therapeutic and conduct clinical studies to further substantiate its safety and efficacy beginning in neuropsychiatric disorders."
• "The clinical studies of the therapeutic are expected to require an investment of up to $1,000,000 and up to two years to finalize."
• "Our future plans include securing additional funding sources."

Industry Context

The company operates in the evolving and highly regulated cannabis and cannabinoid therapeutics industry. Its shift from general cannabis delivery systems to a focus on novel cannabinoid therapeutics for neuropsychiatric disorders, in partnership with a reputable medical center like Shaare Zedek, indicates an attempt to target a high-value, research-intensive segment of the market. However, the industry is capital-intensive, and the company's severe financial distress and lack of revenue suggest it is struggling to compete or execute its strategy effectively, especially compared to more established or better-funded players in the pharmaceutical or biotech cannabis space.

Comparison to Industry Standards

• The company's complete lack of revenue stands in stark contrast to many publicly traded cannabis companies, even smaller ones, which typically report some level of sales, indicating a pre-revenue or early-stage development phase that has persisted for an extended period.
• The significant net loss of $633,270 for six months, coupled with only $26,712 in cash, is indicative of severe financial distress, far below the liquidity and profitability metrics of even struggling industry peers.
• The reliance on converting debt into equity at highly dilutive rates (e.g., 275,000,000 shares for $97,200 principal) is a common characteristic of distressed micro-cap companies, but the scale of dilution (over 50% increase in shares outstanding in six months) is extreme compared to typical capital raises or debt conversions in the broader biotech or cannabis sectors.
• The stated need for up to $1,000,000 for clinical studies over two years is a relatively modest sum for drug development, suggesting either a very early-stage program or a highly focused, limited scope, which could be a positive for capital efficiency if successful, but is dwarfed by the R&D budgets of major pharmaceutical or well-funded biotech companies like GW Pharmaceuticals (now part of Jazz Pharmaceuticals) which invested hundreds of millions in cannabinoid drug development.
• The company's ongoing material weaknesses in internal control over financial reporting, dating back to March 2022, are a significant governance red flag and fall below the standards expected of publicly traded companies, regardless of size, and are not typically seen in well-managed industry players.

Corporate Governance

Related Party Transactions

• Loans payable to related parties (Elisha Kalfa and Yonah Kalfa, Fernando Bisker and Sigalush, LLC) totaling $260,000 as of June 30, 2025. These loans are non-interest bearing and are to be repaid after the company raises at least $1,500,000 or generates sufficient revenue. Lenders have the option to convert loans into common stock if capital is insufficient.
• Officers compensation of $60,000 for the six months ended June 30, 2025, and accrued officers compensation of $430,350 as of June 30, 2025.

Stakeholder Impact

• **Shareholders**: Significant negative impact due to substantial dilution from common stock issuances for debt conversion and compensation (over 50% increase in shares outstanding in six months), coupled with a rapidly increasing net loss and explicit going concern doubt, which could lead to further share price depreciation or potential loss of investment.
• **Creditors/Noteholders**: Those holding convertible notes have seen their debt converted into highly dilutive equity, and the company has incurred significant default penalties and interest, indicating a high risk of non-payment or unfavorable conversion terms.
• **Employees/Management**: Accrued officers compensation has increased, but the company's severe financial distress and going concern doubt raise questions about the long-term stability of employment and ability to pay compensation.
• **Suppliers/Vendors**: The company's low cash balance and negative working capital suggest a high risk of delayed payments or inability to meet future obligations, potentially impacting relationships with suppliers.

Next Steps

• Conduct clinical studies on the cannabinoid-based therapeutic for neuropsychiatric disorders.
• Commercialize the cannabinoid-based therapeutic.
• Concentrate on cannabis-related investment and development opportunities through direct equity investments, joint ventures, licensing agreements, or acquisitions.
• Secure additional funding sources to address liquidity and going concern issues.
• Implement remedial measures to address identified material weaknesses in internal control over financial reporting, as capital resources permit.

Key Dates

Recommendation

The company's financial position is dire, marked by zero revenue, a rapidly escalating net loss, critically low cash reserves, and a substantial increase in liabilities, including significant default penalties. The explicit disclosure of 'substantial doubt about our ability to continue as a going concern' is a severe red flag. Furthermore, the massive dilution of existing shareholders through debt-to-equity conversions, coupled with persistent internal control weaknesses, indicates a high-risk, unsustainable business model. For a seasoned investor, these factors collectively point to a strong sell recommendation, as the likelihood of further value erosion or complete loss of investment is exceptionally high.

Keywords

Cannabis, Cannabinoid therapeutics, Neuropsychiatric disorders, Autism, Schizophrenia, Parkinson's disease, Alzheimer's disease, Drug delivery, Biotechnology, SEC filing, 10-Q, Financial results, Going concern, Dilution, Debt conversion